RCKT
Rocket Pharmaceuticals Inc

3,110
Mkt Cap
$425.14M
Volume
1.68M
52W High
$18.17
52W Low
$2.19
PE Ratio
-1.57
RCKT Fundamentals
Price
$3.94
Prev Close
$3.85
Open
$3.90
50D MA
$3.42
Beta
1.21
Avg. Volume
2.07M
EPS (Annual)
-$2.73
P/B
1.20
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
Zacks·13d ago
News Placeholder
More News
News Placeholder
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Business Wire·14d ago
News Placeholder
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Business Wire·17d ago
News Placeholder
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy
The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya.
Stocktwits·25d ago
News Placeholder
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
Zacks·2mo ago
News Placeholder
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients
The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys.
Stocktwits·2mo ago
News Placeholder
Why Is Rocket Pharma Stock Up 25% Pre-Market Today?
The U.S. Food and Drug Administration has lifted the clinical hold on the company’s mid-stage study of RP-A501 for the treatment of Danon disease.
Stocktwits·2mo ago
News Placeholder
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
Zacks·3mo ago
News Placeholder
RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.
Zacks·4mo ago
News Placeholder
RCKT Stock Tanks on Patient Death in Danon Disease Study
Zacks·5mo ago

Latest RCKT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.